We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Genetic Changes Identified in Patients Who Progress to Esophageal Cancer

By LabMedica International staff writers
Posted on 03 May 2022

Barrett’s esophagus (BE), a predominantly benign metaplasia that arises in the esophagus in response to chronic gastric reflux, also develops somatic mutations, but can further evolve extensive genomic alterations which confer significantly increased risk of progression to esophageal adenocarcinoma (ESAD). More...

Cancer-only studies have uncovered a vast array of genomic alterations in cancer, but are unable to provide a direct comparison of somatic genome evolution of benign neoplastic tissue in non-progressing patients from those who were ultimately diagnosed with cancer. Barrett’s esophagus is an excellent in vivo model in which to study these genome dynamics.

A large team of medical scientists led by the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) designed a case-control study was with 80 participants diagnosed with Barrett’s esophagus (BE). The demographics of the study were typical of BE and ESAD with 72 males and eight females, with the average age at T1 of 65.5 years (range 43-82) for cancer outcome (CO) and 66.1 years (range 41-87) for non-cancer outcome (NCO).

The investigators collected for each time point two fresh-frozen endoscopic biopsies, independent of those used for histologic evaluation, were within the histologically defined regions of Barrett’s esophageal tissue for whole-genome sequencing (WGS). Normal controls from each participant were sequenced from either blood (N = 62) or normal gastric biopsies when blood was not available (N = 18) and analyzed by 30X WGS and 2.5 M SNP array for paired analysis. Somatic chromosome alterations (chromosome copy number and cnLOH) were assessed in BE and control biopsies using the Omni 2.5 M 8v1.3 array (Illumina, San Diego, CA, USA). Several other molecular techniques were also employed.

The scientists reported that the same somatic mutational processes were active in Barrett’s tissue regardless of outcome, with high levels of mutation, ESAD gene and focal chromosomal alterations, and similar mutational signatures. The critical distinction between stable Barrett’s versus those who progress to cancer was acquisition and expansion of TP53−/− cell populations having complex structural variants and high-level amplifications, which were detectable up to six years prior to a cancer diagnosis.

Thomas G. Paulson, PhD, a senior staff scientist who co-led the project said, “Most progressors had two hits in TP53. Two hits would suggest a person is at very high risk for progressing from BE to cancer, though occasionally a person with one hit may also progress. Patients who progressed to cancer also had TP53 mutations in larger regions of tissue, compared to the single-hit, localized lesions in non-progressing patients. If both copies of TP53 in a person’s cells are broken, it’s very difficult for them to fix damaged DNA. This leads to duplications, deletions or reshuffling of large pieces of DNA.” In fact, the team saw that BE cells in patients who progressed to esophageal cancer were much more likely to contain these large, complex changes than cells from those who never progressed.

The authors concluded that their findings reveal the timing of common somatic genome dynamics in stable Barrett’s esophagus and define key genomic features specific to progression to esophageal adenocarcinoma, both of which are critical for cancer prevention and early detection strategies. The study was published on April 28, 2022 in the journal Nature Communications.

Related Links:
Fred Hutchinson Cancer Research Center 
Illumina


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Portable Electronic Pipette
Mini 96
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.